Navigation Links
Monogram Announces Third Quarter 2007 Financial Results
Date:10/24/2007

d our other products by the FDA, and activities expected to occur in connection with the Pfizer collaboration. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may not use a molecular diagnostic for patient selection for maraviroc or other HIV drugs; risks related to the implementation of the collaboration with Pfizer; risks related to our ability to recognize revenue from activities under the collaboration with Pfizer; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials for CCR5 inhibitors, entry inhibitors or integrase inhibitors; the risk that our Trofile Assay may not be utilized for patient use with maraviroc and other CCR5 inhibitors; the risk that our VeraTag assays may not predict response to particular therapeutic agents; the risk that we may not be able to obtain additional cohorts of patient samples for additional VeraTag studies, our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; the timing and ultimate size of pharmaceutical company clinical trials; whether payers will a
'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
(Date:7/29/2015)... ... 2015 , ... Rainbow Scientific, Inc. (RSI), a North American ... BI’s line of human mesenchymal stem cell (hMSC) differentiation media, MSC go ... complete system for multipotency evaluation of hMSCs and reliable induction of hMSCs into ...
(Date:7/28/2015)... ... July 29, 2015 , ... The new Xsample 530 sample changer for vials can ... of liquid viscosities – from less than 12,000 mPas (internal air) up to 36,000 (external ... What immediately catches the eye about Xsample 530 is its removable magazine, which is easily ...
(Date:7/28/2015)... DUBLIN , July 21, 2015 ... ) has announced the addition of the ... report to their offering. Globally, ... applications including immuno-phenotyping, cell proliferation, cancer, and stem ... in clinical applications primarily because of demand from ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3New Moves in Automatic Sample Handling: Introducing Xsample 530 2Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2
... in Detecting ... Validated Trofile, SOUTH SAN FRANCISCO, Calif., Dec. 19 ... that Pfizer Inc (NYSE:,PFE), the manufacturer of Selzentry(TM) (maraviroc), ... Trofile Assay and Pathway,Diagnostics, SensiTrop Assay. Pfizer concluded, based ...
... Inc. enters into an exclusive, distribution agreement with AZPA International Inc. ... ... Zealand -, LAVAL, QC, Dec. 19 /PRNewswire-FirstCall/ - Neptune ... it has entered into an exclusive distribution agreement with,AZPA International Inc. ...
... MATEO, Calif., Dec. 19 BioForm Medical,Inc. (Nasdaq: ... will present a company overview at the upcoming 26th ... BioForm,Medical,s presentation will take place on Monday, January 7th, ... Westin St. Francis Hotel in San Francisco,CA., A ...
Cached Biology Technology:Study Reaffirms Superiority of Trofile(TM) Assay 2Study Reaffirms Superiority of Trofile(TM) Assay 3Study Reaffirms Superiority of Trofile(TM) Assay 4Study Reaffirms Superiority of Trofile(TM) Assay 5Study Reaffirms Superiority of Trofile(TM) Assay 6Nationwide product launch of NKO(R) planned for February 2008 in Australia and New Zealand 2Nationwide product launch of NKO(R) planned for February 2008 in Australia and New Zealand 3BioForm Medical to Present at the 2008 JPMorgan Healthcare Conference on January 7, 2008 2
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
(Date:7/9/2015)... Research and Markets( ... "Biometrics for Banking; Market & Technology Analysis, ... their offering. The adoption for banking ... and the forecast is that by 2020 it ... involved in delivering biometric systems to the banking ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... today announced BD & Guidepoint Mentor, ... free access to Guidepoint,s expert network services. ... developing cutting-edge technologies to improve healthcare delivery and outcomes ... manager, each start-up entrepreneur will be able to directly ...
Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... the body's first line of defense against bacterial infections ... systems, according to researchers at the Indiana University School ... of the Journal of Biological Chemistry, Roman Dziarski, Ph.D., ... be used to develop medications that could boost the ...
... remains one of the deadliest threats to public health. ... disease, which is caused by the microorganism Mycobacterium tuberculosis. ... and more and more bacterial strains have developed resistance ... European Molecular Biology Laboratory (EMBL) and the Max Planck ...
... revealed early signs of emphysema in smokers with no external ... the June issue of Radiology. The study, supported by the ... (MRI) technique that appears to be much more sensitive to ... tomography (CT). , "With this technology, we have shown that ...
Cached Biology News:New potential drug target in tuberculosis 2New MRI technique shows emphysema in asymptomatic smokers 2
Zebrafish Vitellogenin ELISA System, 96 wells. ELISARange: 0.5-100 ng/ml.Sensitivity: 0.3 ng/ml.Sample volume: 100 ul.Suitable for use with Zebrafish plasma samples.3-h protocol.Store at 2-8 C. Categ...
... capped transcripts with the translation boosting Cap ... 100% capped (versus 40% to 80% capped ... about 2 hours. mScript™ also features the ... to be up to 50% more efficient ...
Porcine parvovirus and mycoplasma tested. Contains 0.5 g/L of trypsin (1:250) and 0.2 g/L of EDTA4Na in Hanks' Balanced Salt Solution without CaCl2 MgCl2 6H2O and MgSO4 7H2O. Contains phenol red....
...
Biology Products: